Prometic Life Sciences Inc.

10:31 AM EST - Prometic Life Sciences Inc. : Announced the publication of a paper further elucidating the mechanism of action of its lead drug candidate, PBI-4050, on liver fibrosis in the Journal of Pharmacology and Experimental Therapeutics. The paper entitled " PBI-4050 reduces stellate cell activation and liver fibrosis through modulation of intracellular ATP levels and LKB1-AMPK-mTOR pathway " details the antifibrotic signaling pathway modulated by PBI-4050. Prometic Life Sciences Inc. shares T.PLI are trading down $0.02 at $0.68.